Couldn't agree more
Growing is a high capital / agricultural out come - big upfront costs, declining crop value as increasing supply is a function of all the money raised in the space, especially in Canada over last six months. The laws of diminishing returns will effect all the companies focused on growing.
The real value that has emerged in the US is where you build brand from either the product itself or distribution of white labeled product
This is the key issue missed by many it seems investing in the space.
For Australia: The areas that will provide the most differentiation will be 1) relationship with doctors 2) the product/brand/distribution strategy
That is why MDC and AC8 look most likely to succeed. CAN also good I understand but have not done the work on them as they appear to be focused more on growing
The problem with MDC is the recent issue / Bell's took all the money they could, no doubt as their fee was based on funds raised, not on how well it performed post issue. There are large blocks now being crossed (Friday and Today) and that will hopefully start clearing wrong investors off the register.
Add to My Watchlist
What is My Watchlist?
